MOYA Bio is developing novel E1 inhibitors for solid and hematological malignancies.

Scientific approach

Antagonism of E1 enzymes, which instigate the different Ubiquitin-Like cascades, has been highlighted as a promising therapeutic approach in cancer.

The proprietary compounds developed by the company modulate the Ubiquitin and Ubiquitin-Like pathways in a targeted and selective manner and aim to induce direct anti-tumor effects as well as increase the impact of additional treatment modalities.

link to Moya Bio page

Indications

NSCLC

Team

Eyal Ben Ami, PhD – CSO

Orli Even-Or, PhD – Director of Biology

Scroll to top